HRP20030765B1 - Insulin preparations, which do not contain any zinc or only a small quantity of zinc and which have an improved stability - Google Patents
Insulin preparations, which do not contain any zinc or only a small quantity of zinc and which have an improved stabilityInfo
- Publication number
- HRP20030765B1 HRP20030765B1 HR20030765A HRP20030765A HRP20030765B1 HR P20030765 B1 HRP20030765 B1 HR P20030765B1 HR 20030765 A HR20030765 A HR 20030765A HR P20030765 A HRP20030765 A HR P20030765A HR P20030765 B1 HRP20030765 B1 HR P20030765B1
- Authority
- HR
- Croatia
- Prior art keywords
- zinc
- contain
- small quantity
- improved stability
- insulin preparations
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 title abstract 3
- 239000011701 zinc Substances 0.000 title abstract 3
- 229910052725 zinc Inorganic materials 0.000 title abstract 3
- 102000004877 Insulin Human genes 0.000 title abstract 2
- 108090001061 Insulin Proteins 0.000 title abstract 2
- 229940125396 insulin Drugs 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract 3
- 239000004094 surface-active agent Substances 0.000 abstract 3
- 150000002148 esters Chemical class 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 abstract 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 abstract 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 1
- 150000002170 ethers Chemical class 0.000 abstract 1
- 229930195729 fatty acid Natural products 0.000 abstract 1
- 239000000194 fatty acid Substances 0.000 abstract 1
- 150000004665 fatty acids Chemical class 0.000 abstract 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000000600 sorbitol Substances 0.000 abstract 1
- 150000005846 sugar alcohols Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10114178A DE10114178A1 (de) | 2001-03-23 | 2001-03-23 | Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität |
| PCT/EP2002/002625 WO2002076495A1 (de) | 2001-03-23 | 2002-03-09 | Zinkfreie und zinkarme insulinzubereitungen mit verbesserter stabilität |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP20030765A2 HRP20030765A2 (en) | 2005-06-30 |
| HRP20030765B1 true HRP20030765B1 (en) | 2011-10-31 |
Family
ID=7678654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20030765A HRP20030765B1 (en) | 2001-03-23 | 2003-09-22 | Insulin preparations, which do not contain any zinc or only a small quantity of zinc and which have an improved stability |
Country Status (32)
| Country | Link |
|---|---|
| US (5) | US6960561B2 (me) |
| EP (2) | EP1381385B1 (me) |
| JP (1) | JP4231292B2 (me) |
| KR (2) | KR100987311B1 (me) |
| CN (1) | CN1273187C (me) |
| AR (2) | AR033059A1 (me) |
| AT (1) | ATE497777T1 (me) |
| AU (1) | AU2002302409B2 (me) |
| BR (1) | BRPI0208210B8 (me) |
| CA (1) | CA2441260C (me) |
| CY (2) | CY1111413T1 (me) |
| DE (2) | DE10114178A1 (me) |
| DK (2) | DK1381385T3 (me) |
| ES (2) | ES2360505T3 (me) |
| HK (1) | HK1061521A1 (me) |
| HR (1) | HRP20030765B1 (me) |
| HU (1) | HU228847B1 (me) |
| IL (2) | IL158057A0 (me) |
| ME (1) | ME00408B (me) |
| MX (1) | MXPA03007942A (me) |
| MY (1) | MY129417A (me) |
| NO (1) | NO326780B1 (me) |
| NZ (1) | NZ528335A (me) |
| PE (1) | PE20020968A1 (me) |
| PL (1) | PL205465B1 (me) |
| PT (2) | PT1381385E (me) |
| RS (1) | RS51579B (me) |
| RU (1) | RU2311922C2 (me) |
| SI (1) | SI1381385T1 (me) |
| TW (1) | TWI301761B (me) |
| WO (1) | WO2002076495A1 (me) |
| ZA (1) | ZA200306637B (me) |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE321783T1 (de) * | 1997-03-20 | 2006-04-15 | Novo Nordisk As | Zinkfreie insulinkristalle für die verwendung in medikamenten, die über die lunge verabreicht werden. |
| DE10114178A1 (de) | 2001-03-23 | 2002-10-10 | Aventis Pharma Gmbh | Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität |
| US20050250676A1 (en) * | 2001-11-19 | 2005-11-10 | Aventis Pharma Deutschland Gmbh | Method of activating insulin receptor substrate-2 to stimulate insulin production |
| DE10227232A1 (de) * | 2002-06-18 | 2004-01-15 | Aventis Pharma Deutschland Gmbh | Saure Insulinzubereitungen mit verbesserter Stabilität |
| US7193035B2 (en) | 2002-10-29 | 2007-03-20 | Sanofi-Aventis Deutschland Gmbh | Crystals of insulin analogs and processes for their preparation |
| DE10250297A1 (de) * | 2002-10-29 | 2004-05-19 | Aventis Pharma Deutschland Gmbh | Kristalle von Insulinanaloga und Verfahren zu ihrer Herstellung |
| WO2004096266A1 (en) * | 2003-05-02 | 2004-11-11 | Novo Nordisk A/S | Improved physical stability of insulin formulations |
| PL2107069T3 (pl) | 2003-08-05 | 2013-06-28 | Novo Nordisk As | Nowe pochodne insuliny |
| AU2005209199B2 (en) * | 2004-01-16 | 2008-09-11 | Biodel Inc. | Sublingual drug delivery device |
| EP1720520B1 (en) * | 2004-02-13 | 2010-06-09 | Nod Pharmaceuticals, Inc. | Particles comprising a core of calcium phosphate nanoparticles, a biomolecule and a bile acid, methods of manufacturing, therapeutic use thereof |
| US20080096800A1 (en) * | 2004-03-12 | 2008-04-24 | Biodel, Inc. | Rapid mucosal gel or film insulin compositions |
| ES2398318T3 (es) * | 2004-03-12 | 2013-03-15 | Biodel, Inc. | Composiciones de suministro de fármacos de acción rápida |
| US20080090753A1 (en) | 2004-03-12 | 2008-04-17 | Biodel, Inc. | Rapid Acting Injectable Insulin Compositions |
| AU2005269753B2 (en) | 2004-07-19 | 2011-08-18 | Biocon Limited | Insulin-oligomer conjugates, formulations and uses thereof |
| JP2006087815A (ja) * | 2004-09-27 | 2006-04-06 | Canon Inc | 噴霧方法および該方法に基づく噴霧装置 |
| US20060194762A1 (en) * | 2004-12-23 | 2006-08-31 | Olaf Reer | Composition comprising an epothilone and methods for producing a composition comprising an epothilone |
| US7713929B2 (en) | 2006-04-12 | 2010-05-11 | Biodel Inc. | Rapid acting and long acting insulin combination formulations |
| US8084420B2 (en) | 2005-09-29 | 2011-12-27 | Biodel Inc. | Rapid acting and long acting insulin combination formulations |
| ES2371361T3 (es) * | 2005-12-28 | 2011-12-30 | Novo Nordisk A/S | Composiciones que comprenden una insulina acilada y zinc y método de producción de dichas composiciones. |
| WO2007121318A2 (en) | 2006-04-12 | 2007-10-25 | Emisphere Technologies, Inc. | Formulations for delivering insulin |
| EP2012817A2 (en) | 2006-04-12 | 2009-01-14 | Biodel, Inc. | Rapid acting and long acting insulin combination formulations |
| US7714025B2 (en) * | 2006-05-10 | 2010-05-11 | Arizona Biomedical Research Commission | Modified chalcone compounds as antimitotic agents |
| JP2010525033A (ja) * | 2007-04-30 | 2010-07-22 | ノボ・ノルデイスク・エー／エス | 高濃縮のインスリン溶液及び組成物 |
| WO2008152106A1 (en) * | 2007-06-13 | 2008-12-18 | Novo Nordisk A/S | Pharmaceutical formulation comprising an insulin derivative |
| WO2009065126A2 (en) * | 2007-11-16 | 2009-05-22 | Boston Protein Solutions | Excipients for protein stabilization |
| CA2708762A1 (en) * | 2007-12-11 | 2009-06-18 | Conjuchem Biotechnologies Inc. | Formulation of insulinotropic peptide conjugates |
| EP2229407B1 (de) | 2008-01-09 | 2016-11-16 | Sanofi-Aventis Deutschland GmbH | Neue insulinderivate mit extrem verzögertem zeit- / wirkungsprofil |
| KR101239008B1 (ko) * | 2008-03-31 | 2013-03-04 | 한양대학교 산학협력단 | 바일산 유도체 및 그의 응용 |
| JP2010063762A (ja) * | 2008-09-12 | 2010-03-25 | Yoshiharu Masui | 抗菌消臭剤 |
| HUE037449T2 (hu) | 2008-10-17 | 2018-08-28 | Sanofi Aventis Deutschland | Egy inzulin és egy GLP-1 agonista kombinációja |
| MX2011004357A (es) | 2008-10-30 | 2011-05-23 | Novo Nordisk As | Tratamiento de diabetes mellitus utilizando inyecciones de insulina con una frecuencia de inyeccion menor que a diario. |
| US9060927B2 (en) | 2009-03-03 | 2015-06-23 | Biodel Inc. | Insulin formulations for rapid uptake |
| PT2612677E (pt) * | 2009-06-26 | 2015-09-10 | Novo Nordisk As | Preparação compreendendo insulina, nicotinamida e arginina |
| JP5735960B2 (ja) * | 2009-07-06 | 2015-06-17 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | メチオニンを含むインスリン製剤 |
| WO2011058082A1 (de) | 2009-11-13 | 2011-05-19 | Sanofi-Aventis Deutschland Gmbh | Pharmazeutische zusammensetzung umfassend einen glp-1-agonisten und methionin |
| AR080669A1 (es) | 2009-11-13 | 2012-05-02 | Sanofi Aventis Deutschland | Composicion farmaceutica que comprende un agonista de glp-1, una insulina y metionina |
| CN101912600B (zh) * | 2010-01-11 | 2014-01-29 | 杨国汉 | 改善胰岛素在溶液中稳定性的方法 |
| ES2606554T3 (es) | 2010-08-30 | 2017-03-24 | Sanofi-Aventis Deutschland Gmbh | Uso de AVE0010 para la fabricación de un medicamento para el tratamiento de la diabetes mellitus de tipo 2 |
| DK2632478T3 (da) | 2010-10-27 | 2019-10-07 | Novo Nordisk As | Behandling af diabetes melitus under anvendelse af insulinindsprøjtninger indgivet med varierende indsprøjtningsintervaller |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| BR112014004726A2 (pt) | 2011-08-29 | 2017-04-04 | Sanofi Aventis Deutschland | combinação farmacêutica para uso no controle glicêmico em pacientes de diabetes tipo 2 |
| TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
| BR112014010139A2 (pt) | 2011-10-27 | 2017-04-25 | Univ Case Western Reserve | formulação farmacêutica, método de redução do nível de açúcar no sangue de um paciente e polipeptídeo |
| EP2919804B1 (fr) | 2012-11-13 | 2018-01-31 | Adocia | Formulation à action rapide d'insuline comprenant un composé anionique substitué |
| TWI780236B (zh) | 2013-02-04 | 2022-10-11 | 法商賽諾菲公司 | 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物 |
| MY181626A (en) | 2013-04-03 | 2020-12-29 | Sanofi Sa | Treatment of diabetes mellitus by long-acting formulations of insulins |
| JP2016519127A (ja) | 2013-04-30 | 2016-06-30 | ノヴォ ノルディスク アー／エス | 新規投与レジメン |
| TW201605489A (zh) * | 2013-10-25 | 2016-02-16 | 賽諾菲公司 | 賴谷胰島素（ｉｎｓｕｌｉｎ ｇｌｕｌｉｓｉｎｅ）的穩定調配物 |
| SG11201604708VA (en) | 2014-01-09 | 2016-07-28 | Sanofi Sa | Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives |
| AU2015205624A1 (en) | 2014-01-09 | 2016-07-14 | Sanofi | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives |
| CN105899190B (zh) | 2014-01-09 | 2022-06-14 | 赛诺菲 | 门冬胰岛素的稳定化药物制剂 |
| AR099569A1 (es) | 2014-02-28 | 2016-08-03 | Novo Nordisk As | Derivados de insulina y los usos médicos de estos |
| US10314911B2 (en) * | 2014-04-08 | 2019-06-11 | Healthpartners Research & Education | Methods for protecting and treating traumatic brain injury, concussion and brain inflammation with intranasal insulin |
| PL3229828T3 (pl) | 2014-12-12 | 2023-07-31 | Sanofi-Aventis Deutschland Gmbh | Formulacja o ustalonym stosunku insuliny glargine/liksysenatydu |
| AR102869A1 (es) | 2014-12-16 | 2017-03-29 | Lilly Co Eli | Composiciones de insulina de rápida acción |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
| JP2018531900A (ja) | 2015-08-25 | 2018-11-01 | ノヴォ ノルディスク アー／エス | 新規インスリン誘導体及びその医学的使用 |
| WO2017032797A1 (en) | 2015-08-25 | 2017-03-02 | Novo Nordisk A/S | Novel insulin derivatives and the medical uses hereof |
| JP2018531901A (ja) | 2015-08-25 | 2018-11-01 | ノヴォ ノルディスク アー／エス | 新規インスリン誘導体及びその医学的使用 |
| JO3749B1 (ar) | 2015-08-27 | 2021-01-31 | Lilly Co Eli | تركيبات إنسولين سريعة المفعول |
| CN105749292A (zh) * | 2016-02-29 | 2016-07-13 | 苏州市贝克生物科技有限公司 | 促进胰岛素吸收的组合物及其制备方法 |
| GB201607918D0 (en) | 2016-05-06 | 2016-06-22 | Arecor Ltd | Novel formulations |
| KR102482664B1 (ko) | 2016-09-29 | 2022-12-29 | 아레콜 리미티드 | 신규한 제제 |
| GB201707188D0 (en) | 2017-05-05 | 2017-06-21 | Arecor Ltd | Novel formulations |
| GB201707187D0 (en) | 2017-05-05 | 2017-06-21 | Arecor Ltd | Novel formulations |
| GB201707189D0 (en) | 2017-05-05 | 2017-06-21 | Arecor Ltd | Novel formulations |
| CN110662551B (zh) | 2017-06-01 | 2023-07-18 | 伊莱利利公司 | 速效胰岛素组合物 |
| CN111989088A (zh) | 2018-04-04 | 2020-11-24 | 艾瑞克有限公司 | 用于递送胰岛素化合物的医用输注泵系统 |
| US20210113763A1 (en) | 2018-04-04 | 2021-04-22 | Arecor Limited | Medical infusion pump system for the delivery of an insulin compound |
| CN112004521A (zh) | 2018-04-04 | 2020-11-27 | 艾瑞克有限公司 | 用于递送胰岛素化合物的医用输注泵系统 |
| US10335464B1 (en) | 2018-06-26 | 2019-07-02 | Novo Nordisk A/S | Device for titrating basal insulin |
| FR3083700B1 (fr) * | 2018-07-13 | 2021-03-12 | Adocia | Formulation thermostable d'insuline humaine a21g |
| KR20210095165A (ko) | 2018-11-19 | 2021-07-30 | 프로제너티, 인크. | 바이오의약품으로 질환을 치료하기 위한 방법 및 디바이스 |
| CN115176155A (zh) | 2019-10-25 | 2022-10-11 | 塞卡科实验室有限公司 | 指示剂化合物、包括指示剂化合物的装置及其制备和使用方法 |
| CA3159114A1 (en) | 2019-12-11 | 2021-06-17 | Frantisek Hubalek | Novel insulin analogues and uses thereof |
| CN115666704A (zh) | 2019-12-13 | 2023-01-31 | 比奥拉治疗股份有限公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| GB202004814D0 (en) | 2020-04-01 | 2020-05-13 | Arecor Ltd | Novel formulations |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4153689A (en) * | 1975-06-13 | 1979-05-08 | Takeda Chemical Industries, Ltd. | Stable insulin preparation for nasal administration |
| EP0166529A1 (en) * | 1984-05-29 | 1986-01-02 | Eli Lilly And Company | Stabilized insulin formulation |
| EP0200383A2 (en) * | 1985-04-15 | 1986-11-05 | Eli Lilly And Company | An improved method for administering insulin |
| US5606203A (en) * | 1993-01-20 | 1997-02-25 | Kabushiki Kaisha Toshiba | Semiconductor device having Al-Cu wiring lines where Cu concentration is related to line width |
| WO1998042749A1 (en) * | 1997-03-20 | 1998-10-01 | Novo Nordisk A/S | Zinc free insulin crystals for use in pulmonary compositions |
| WO2000074736A1 (en) * | 1999-06-04 | 2000-12-14 | Delrx Pharmaceutical Corporation | Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same |
Family Cites Families (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3758683A (en) | 1971-04-30 | 1973-09-11 | R Jackson | Insulin product |
| US3868358A (en) | 1971-04-30 | 1975-02-25 | Lilly Co Eli | Protamine-insulin product |
| GB1527605A (en) | 1975-08-20 | 1978-10-04 | Takeda Chemical Industries Ltd | Insulin preparation for intranasal administration |
| DE3064888D1 (en) | 1979-04-30 | 1983-10-27 | Hoechst Ag | Aqueous solutions of proteins stable against denaturization, process for their manufacture, and their utilization |
| US4783441A (en) | 1979-04-30 | 1988-11-08 | Hoechst Aktiengesellschaft | Aqueous protein solutions stable to denaturation |
| JPS55153712A (en) | 1979-05-18 | 1980-11-29 | Kao Corp | Insulin pharmaceutical preparation and its production |
| DE3033127A1 (de) | 1980-09-03 | 1982-04-08 | Hoechst Ag, 6000 Frankfurt | Neue analoga des insulins |
| EP0083619A1 (en) | 1981-07-17 | 1983-07-20 | Nordisk Insulinlaboratorium | A stable aqueous, therapeutic insulin preparation and a process for preparing it |
| NL193099C (nl) | 1981-10-30 | 1998-11-03 | Novo Industri As | Gestabiliseerde insuline-oplossing. |
| DE3316363A1 (de) | 1983-05-05 | 1984-11-08 | Deutsche Babcock Anlagen Ag, 4200 Oberhausen | Walzenrost fuer muellverbrennungsanlagen |
| DE3326472A1 (de) | 1983-07-22 | 1985-02-14 | Hoechst Ag, 6230 Frankfurt | Neue insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus |
| DE3326473A1 (de) | 1983-07-22 | 1985-01-31 | Hoechst Ag, 6230 Frankfurt | Pharmazeutisches mittel zur behandlung des diabetes mellitus |
| DE3327713A1 (de) | 1983-07-29 | 1985-02-07 | Hoechst Ag, 6230 Frankfurt | Wasserloesliche disazoverbindungen, verfahren zu deren herstellung und ihre verwendung als farbstoffe |
| DE3327709A1 (de) | 1983-07-29 | 1985-02-07 | Hoechst Ag, 6230 Frankfurt | Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung |
| US4839341A (en) | 1984-05-29 | 1989-06-13 | Eli Lilly And Company | Stabilized insulin formulations |
| DE3576120D1 (de) | 1984-06-09 | 1990-04-05 | Hoechst Ag | Insulinzubereitungen, verfahren zu deren herstellung und deren verwendung. |
| KR860001166B1 (ko) * | 1984-06-15 | 1986-08-20 | 곽성일 | 신발 결착용 구멍쇠의 제조방법 |
| DE3440988A1 (de) | 1984-11-09 | 1986-07-10 | Hoechst Ag, 6230 Frankfurt | Verfahren zur spaltung von peptiden und proteinen an der methionyl-bindung |
| US5008241A (en) | 1985-03-12 | 1991-04-16 | Novo Nordisk A/S | Novel insulin peptides |
| DK113585D0 (da) | 1985-03-12 | 1985-03-12 | Novo Industri As | Nye peptider |
| DK347086D0 (da) | 1986-07-21 | 1986-07-21 | Novo Industri As | Novel peptides |
| DE3526995A1 (de) | 1985-07-27 | 1987-02-05 | Hoechst Ag | Fusionsproteine, verfahren zu ihrer herstellung und ihre verwendung |
| PH25772A (en) | 1985-08-30 | 1991-10-18 | Novo Industri As | Insulin analogues, process for their preparation |
| DE3541856A1 (de) | 1985-11-27 | 1987-06-04 | Hoechst Ag | Eukaryotische fusionsproteine, ihre herstellung und verwendung sowie mittel zur durchfuehrung des verfahrens |
| US5496924A (en) | 1985-11-27 | 1996-03-05 | Hoechst Aktiengesellschaft | Fusion protein comprising an interleukin-2 fragment ballast portion |
| CA1275922C (en) | 1985-11-28 | 1990-11-06 | Harunobu Amagase | Treatment of cancer |
| DE3544295A1 (de) | 1985-12-14 | 1987-06-19 | Bayer Ag | Thermoplastische formmassen mit hoher kriechstromfestigkeit |
| PH23446A (en) | 1986-10-20 | 1989-08-07 | Novo Industri As | Peptide preparations |
| WO1988006599A1 (en) | 1987-02-25 | 1988-09-07 | Novo Industri A/S | Novel insulin derivatives |
| US5034415A (en) | 1987-08-07 | 1991-07-23 | Century Laboratories, Inc. | Treatment of diabetes mellitus |
| DE3726655A1 (de) | 1987-08-11 | 1989-02-23 | Hoechst Ag | Verfahren zur isolierung basischer proteine aus proteingemischen, welche solche basischen proteine enthalten |
| DK257988D0 (da) | 1988-05-11 | 1988-05-11 | Novo Industri As | Nye peptider |
| US6875589B1 (en) | 1988-06-23 | 2005-04-05 | Hoechst Aktiengesellschaft | Mini-proinsulin, its preparation and use |
| DE3827533A1 (de) | 1988-08-13 | 1990-02-15 | Hoechst Ag | Pharmazeutische zubereitung zur behandlung des diabetes mellitus |
| DE3837825A1 (de) | 1988-11-08 | 1990-05-10 | Hoechst Ag | Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung |
| KR910700262A (ko) | 1988-12-23 | 1991-03-14 | 안네 제케르 | 사람 인슐린 유사체 |
| US4994439A (en) | 1989-01-19 | 1991-02-19 | California Biotechnology Inc. | Transmembrane formulations for drug administration |
| NZ232375A (en) | 1989-02-09 | 1992-04-28 | Lilly Co Eli | Insulin analogues modified at b29 |
| US5514646A (en) | 1989-02-09 | 1996-05-07 | Chance; Ronald E. | Insulin analogs modified at position 29 of the B chain |
| US5358857A (en) | 1989-08-29 | 1994-10-25 | The General Hospital Corp. | Method of preparing fusion proteins |
| US5397771A (en) | 1990-05-10 | 1995-03-14 | Bechgaard International Research And Development A/S | Pharmaceutical preparation |
| ATE164080T1 (de) | 1990-05-10 | 1998-04-15 | Bechgaard Int Res | Pharmazeutische zubereitung enthaltend n- glykofurole und n-äthylenglykole |
| DK155690D0 (da) | 1990-06-28 | 1990-06-28 | Novo Nordisk As | Nye peptider |
| DK10191D0 (da) | 1991-01-22 | 1991-01-22 | Novo Nordisk As | Hidtil ukendte peptider |
| US5614219A (en) | 1991-12-05 | 1997-03-25 | Alfatec-Pharma Gmbh | Oral administration form for peptide pharmaceutical substances, in particular insulin |
| US6468959B1 (en) | 1991-12-05 | 2002-10-22 | Alfatec-Pharm Gmbh | Peroral dosage form for peptide containing medicaments, in particular insulin |
| DE59206324D1 (de) | 1991-12-05 | 1996-06-20 | Alfatec Pharma Gmbh | Pharmazeutisch applizierbares nanosol und verfahren zu seiner herstellung |
| DK0600372T3 (da) | 1992-12-02 | 1997-08-11 | Hoechst Ag | Fremgangsmåde til fremstilling af proinsulin med korrekt forbundne cystinbroer. |
| CA2151134A1 (en) | 1992-12-18 | 1994-07-07 | Ronald Eugene Chance | Insulin analogs |
| DE4400709B4 (de) * | 1993-01-13 | 2005-06-23 | Denso Corp., Kariya | Schraubenfestziehvorrichtung |
| US5506203C1 (en) * | 1993-06-24 | 2001-02-06 | Astra Ab | Systemic administration of a therapeutic preparation |
| US5534488A (en) | 1993-08-13 | 1996-07-09 | Eli Lilly And Company | Insulin formulation |
| DE4405179A1 (de) | 1994-02-18 | 1995-08-24 | Hoechst Ag | Verfahren zur Gewinnung von Insulin mit korrekt verbundenen Cystinbrücken |
| US5474978A (en) | 1994-06-16 | 1995-12-12 | Eli Lilly And Company | Insulin analog formulations |
| US5559094A (en) | 1994-08-02 | 1996-09-24 | Eli Lilly And Company | AspB1 insulin analogs |
| PT779806E (pt) | 1994-09-09 | 2001-02-28 | Takeda Chemical Industries Ltd | Preparacao de libertacao sustentada contendo um sal metalico de um peptido |
| US5547929A (en) | 1994-09-12 | 1996-08-20 | Eli Lilly And Company | Insulin analog formulations |
| US5707641A (en) | 1994-10-13 | 1998-01-13 | Pharmaderm Research & Development Ltd. | Formulations comprising therapeutically-active proteins or polypeptides |
| US5824638A (en) | 1995-05-22 | 1998-10-20 | Shire Laboratories, Inc. | Oral insulin delivery |
| JP2002514892A (ja) | 1995-06-08 | 2002-05-21 | コブラ セラピューティクス リミテッド | 遺伝子治療における合成ウイルス様粒子の使用 |
| CA2224381A1 (en) | 1995-06-27 | 1997-01-16 | Takeda Chemical Industries, Ltd. | Method of producing sustained-release preparation |
| DE19545257A1 (de) | 1995-11-24 | 1997-06-19 | Schering Ag | Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln |
| US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| US5948751A (en) | 1996-06-20 | 1999-09-07 | Novo Nordisk A/S | X14-mannitol |
| US5866538A (en) | 1996-06-20 | 1999-02-02 | Novo Nordisk A/S | Insulin preparations containing NaCl |
| US5783556A (en) | 1996-08-13 | 1998-07-21 | Genentech, Inc. | Formulated insulin-containing composition |
| DE19707245A1 (de) * | 1997-02-25 | 1998-08-27 | Patent Treuhand Ges Fuer Elektrische Gluehlampen Mbh | Verfahren zur Herstellung einer elektrischen Glühlampe |
| US6310038B1 (en) * | 1997-03-20 | 2001-10-30 | Novo Nordisk A/S | Pulmonary insulin crystals |
| US6043214A (en) | 1997-03-20 | 2000-03-28 | Novo Nordisk A/S | Method for producing powder formulation comprising an insulin |
| CO4750643A1 (es) | 1997-06-13 | 1999-03-31 | Lilly Co Eli | Formulacion estable de la insulina que contiene l-arginina y protamina |
| DE19726167B4 (de) | 1997-06-20 | 2008-01-24 | Sanofi-Aventis Deutschland Gmbh | Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung |
| ZA989744B (en) | 1997-10-31 | 2000-04-26 | Lilly Co Eli | Method for administering acylated insulin. |
| AU1302499A (en) | 1997-11-12 | 1999-05-31 | Alza Corporation | Buffered drug formulations for transdermal electrotransport delivery |
| DE69924232D1 (de) | 1998-01-09 | 2005-04-21 | Novo Nordisk As | Stabilisierte insulin-zubereitungen |
| US6211144B1 (en) * | 1998-10-16 | 2001-04-03 | Novo Nordisk A/S | Stable concentrated insulin preparations for pulmonary delivery |
| JP2002527488A (ja) | 1998-10-16 | 2002-08-27 | ノボ ノルディスク アクティーゼルスカブ | メントールを含有する肺送達のためのインスリン製剤 |
| US6635617B1 (en) | 1998-10-16 | 2003-10-21 | Novo Nordisk A/S | Insulin preparations for pulmonary delivery containing menthol |
| CZ20011134A3 (cs) | 1998-10-16 | 2001-08-15 | Novo Nordisk A/S | Stabilní koncentrované insulinové přípravky pro plicní podávání |
| US6489292B1 (en) | 1998-11-18 | 2002-12-03 | Novo Nordisk A/S | Stable aqueous insulin preparations without phenol and cresol |
| DE69914934T2 (de) | 1998-11-18 | 2005-01-05 | Novo Nordisk A/S | Stabile, wässrige insulin-präparate ohne phenol und cresol |
| DE19908041A1 (de) * | 1999-02-24 | 2000-08-31 | Hoecker Hartwig | Kovalent verbrückte Insulindimere |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| EP1196189A2 (en) | 1999-06-25 | 2002-04-17 | Medtronic MiniMed, Inc. | Multiple agent diabetes therapy |
| US6309663B1 (en) | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
| EP1214059B1 (en) | 1999-09-21 | 2005-05-25 | Skyepharma Canada Inc. | Surface modified particulate compositions of biologically active substances |
| US6720001B2 (en) | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
| WO2001052937A1 (en) | 2000-01-24 | 2001-07-26 | Medtronic Minimed, Inc. | Mixed buffer system for stabilizing polypeptide formulations |
| WO2001093837A2 (en) | 2000-06-08 | 2001-12-13 | Eli Lilly And Company | Protein powder for pulmonary delivery |
| KR100508695B1 (ko) | 2001-02-13 | 2005-08-17 | 한국과학기술연구원 | 인슐린의 경구투여용 제형과 그의 제조방법 |
| DE10114178A1 (de) * | 2001-03-23 | 2002-10-10 | Aventis Pharma Gmbh | Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität |
| CN1160122C (zh) * | 2001-04-20 | 2004-08-04 | 清华大学 | 一种制备口服胰岛素油相制剂的方法 |
| US20040265268A1 (en) | 2001-08-18 | 2004-12-30 | Deepak Jain | Compositions and methods for skin rejuvenation and repair |
| US20050013867A1 (en) | 2001-10-19 | 2005-01-20 | Lehrman S. Russ | Use of proton sequestering agents in drug formulations |
| US20050123509A1 (en) | 2001-10-19 | 2005-06-09 | Lehrman S. R. | Modulating charge density to produce improvements in the characteristics of spray-dried proteins |
| US20060287221A1 (en) | 2003-11-13 | 2006-12-21 | Novo Nordisk A/S | Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia |
-
2001
- 2001-03-23 DE DE10114178A patent/DE10114178A1/de not_active Ceased
-
2002
- 2002-03-09 IL IL15805702A patent/IL158057A0/xx unknown
- 2002-03-09 BR BR0208210-1 patent/BRPI0208210B8/pt not_active IP Right Cessation
- 2002-03-09 RS YU73503A patent/RS51579B/sr unknown
- 2002-03-09 SI SI200230934T patent/SI1381385T1/sl unknown
- 2002-03-09 HU HU0303596A patent/HU228847B1/hu unknown
- 2002-03-09 AU AU2002302409A patent/AU2002302409B2/en not_active Expired
- 2002-03-09 ME MEP-2008-608A patent/ME00408B/me unknown
- 2002-03-09 KR KR1020037012339A patent/KR100987311B1/ko active IP Right Grant
- 2002-03-09 KR KR1020107011428A patent/KR20100061868A/ko not_active Application Discontinuation
- 2002-03-09 ES ES02729985T patent/ES2360505T3/es not_active Expired - Lifetime
- 2002-03-09 NZ NZ528335A patent/NZ528335A/en not_active IP Right Cessation
- 2002-03-09 EP EP02729985A patent/EP1381385B1/de not_active Expired - Lifetime
- 2002-03-09 PT PT02729985T patent/PT1381385E/pt unknown
- 2002-03-09 PL PL362800A patent/PL205465B1/pl unknown
- 2002-03-09 DK DK02729985.8T patent/DK1381385T3/da active
- 2002-03-09 CA CA2441260A patent/CA2441260C/en not_active Expired - Lifetime
- 2002-03-09 CN CNB02807114XA patent/CN1273187C/zh not_active Expired - Lifetime
- 2002-03-09 JP JP2002575008A patent/JP4231292B2/ja not_active Expired - Lifetime
- 2002-03-09 EP EP10178836A patent/EP2289539B1/de not_active Expired - Lifetime
- 2002-03-09 ES ES10178836T patent/ES2393180T3/es not_active Expired - Lifetime
- 2002-03-09 MX MXPA03007942A patent/MXPA03007942A/es active IP Right Grant
- 2002-03-09 AT AT02729985T patent/ATE497777T1/de active
- 2002-03-09 DK DK10178836.2T patent/DK2289539T3/da active
- 2002-03-09 PT PT10178836T patent/PT2289539E/pt unknown
- 2002-03-09 RU RU2003131187/15A patent/RU2311922C2/ru active
- 2002-03-09 WO PCT/EP2002/002625 patent/WO2002076495A1/de active Application Filing
- 2002-03-09 DE DE50214903T patent/DE50214903D1/de not_active Expired - Lifetime
- 2002-03-21 AR ARP020101020A patent/AR033059A1/es not_active Application Discontinuation
- 2002-03-21 TW TW091105385A patent/TWI301761B/zh not_active IP Right Cessation
- 2002-03-22 PE PE2002000226A patent/PE20020968A1/es not_active Application Discontinuation
- 2002-03-22 US US10/102,862 patent/US6960561B2/en not_active Expired - Lifetime
- 2002-03-22 MY MYPI20021031A patent/MY129417A/en unknown
-
2003
- 2003-08-26 ZA ZA200306637A patent/ZA200306637B/xx unknown
- 2003-09-16 NO NO20034125A patent/NO326780B1/no not_active IP Right Cessation
- 2003-09-22 HR HR20030765A patent/HRP20030765B1/xx not_active IP Right Cessation
- 2003-09-22 IL IL158057A patent/IL158057A/en active IP Right Grant
-
2004
- 2004-06-19 HK HK04104454A patent/HK1061521A1/xx not_active IP Right Cessation
- 2004-12-09 US US11/007,154 patent/US7205276B2/en not_active Expired - Lifetime
- 2004-12-09 US US11/007,155 patent/US7205277B2/en not_active Expired - Lifetime
-
2007
- 2007-03-08 US US11/683,747 patent/US7452860B2/en not_active Expired - Lifetime
-
2008
- 2008-10-06 US US12/285,464 patent/US7696162B2/en not_active Expired - Lifetime
-
2011
- 2011-03-03 CY CY20111100253T patent/CY1111413T1/el unknown
-
2012
- 2012-11-08 CY CY20121101060T patent/CY1113318T1/el unknown
-
2014
- 2014-05-21 AR ARP140102020A patent/AR096376A2/es not_active Application Discontinuation
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4153689A (en) * | 1975-06-13 | 1979-05-08 | Takeda Chemical Industries, Ltd. | Stable insulin preparation for nasal administration |
| EP0166529A1 (en) * | 1984-05-29 | 1986-01-02 | Eli Lilly And Company | Stabilized insulin formulation |
| EP0200383A2 (en) * | 1985-04-15 | 1986-11-05 | Eli Lilly And Company | An improved method for administering insulin |
| US5606203A (en) * | 1993-01-20 | 1997-02-25 | Kabushiki Kaisha Toshiba | Semiconductor device having Al-Cu wiring lines where Cu concentration is related to line width |
| WO1998042749A1 (en) * | 1997-03-20 | 1998-10-01 | Novo Nordisk A/S | Zinc free insulin crystals for use in pulmonary compositions |
| WO2000074736A1 (en) * | 1999-06-04 | 2000-12-14 | Delrx Pharmaceutical Corporation | Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20030765B1 (en) | Insulin preparations, which do not contain any zinc or only a small quantity of zinc and which have an improved stability | |
| BR0311877A (pt) | Preparações ácidas de insulina com estabilidade aperfeiçoada | |
| TR200302105T4 (tr) | Siklosporin, hiyalüronik asit ve polisorbat içeren göz formülasyonları. | |
| DE69734653D1 (de) | Pharmazeutische formulierung, bestehend aus menschlichem wachstumshormon, histidine und einem nichtionischen detergenz | |
| FI820467L (fi) | Farmaceutiska kompositioner som frigoers kontinuerligt | |
| NO20004721L (no) | Bruseformuleringer | |
| DE60134816D1 (de) | Extrakte, Wirkstoffe und pharmazeutische Präparate mit antidiabetischen Eigenschaften und ihre Verwendung | |
| YU78903A (sh) | Upotreba etoksilata masnih alkohola kao promotora penetracije | |
| ES2194679T3 (es) | Composiciones cosmeticas que contienen creatina, carnitina y/o acido piruvico. | |
| AU2513099A (en) | Gel-type disinfectant having a low alcohol content | |
| DE69429964D1 (de) | Feste, therapeutische oder hygienische, mucoadhäsive Zusammensetzung zur Verabreichung durch Auftragen auf der Mund-schleimhaut oder der Nasen-schleimhaut | |
| ES2133775T3 (es) | Composiciones para el lavado de vajillas. | |
| BR0304298A (pt) | Composição contendo um ácido orgânico cosmeticamente ativo e um produto de legume | |
| DE50100958D1 (de) | Stabile, nasal, oral oder sublingual anwendbare pharmazeutische zubereitung enthaltend desmopressin | |
| EP2229957A3 (en) | Stabilization of aqueous compositions of 18f-isotope labelled 2-fluoro-2-deoxy-d-glucose with ethanol | |
| DE50010978D1 (de) | Kosmetische Stiftzubereitung | |
| KR970009581B1 (en) | Composition for topical use containing depolymerized deoxyribonucleic acids in the skin and body cosmetic treathent | |
| BR0014878A (pt) | Composição farmacêutica contendo ciclosonida para aplicação à mucosa | |
| KR930001903A (ko) | 유비데카레논 경구용 수용액 제제 | |
| MY136546A (en) | A pharmaceutical component based on human parathyroid harmone and a pharmaceutical composition for intranasal administration comprising the component | |
| DE60004191D1 (de) | Gelöste pharmazeutische zusammensetzung für die parenterale verabreichung | |
| AU629445B2 (en) | Improvements in or relating to topical compositions containing 1 alpha 25-dihydroxycholecalciferol | |
| YU184090A (sh) | Stabilizovani interferoni leukocita | |
| AU2003224107A1 (en) | Soluble composition containing sporopollenin and the use thereof | |
| GB0112764D0 (en) | Thickened aqueous compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
| PNAN | Change of the applicant name, address/residence |
Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH, DE |
|
| B1PR | Patent granted | ||
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20190207 Year of fee payment: 18 |
|
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20200205 Year of fee payment: 19 |
|
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20210218 Year of fee payment: 20 |
|
| PB20 | Patent expired after termination of 20 years |
Effective date: 20220309 |